Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer.

CANCER RESEARCH（2023）

引用 0|浏览22

暂无评分

摘要

We observed a higher rate of PIK3CA mutations, but no significant difference in ERBB2 alterations, oncogenic pathways, or prognosis, between HER2-low and HER2-0 MBC. If validated, our findings support the conclusion that HER2-low MBC does not represent a unique biological subtype.

查看译文

关键词

tumor dna,breast cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要